Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis

Paolo Fagone, Emanuela Mazzon, Tinatin Chikovani, Andrea Saraceno, Santa Mammana, Giuseppe Colletti, Katia Mangano, Placido Bramanti, Ferdinando Nicoletti

Research output: Contribution to journalArticle

Abstract

Guillain-Barré syndrome (GBS) is an immune-mediated acute disorder of the peripheral nervous system. Despite treatment, there is an associated mortality and severe disability in 9 to 17% of the cases. Decitabine (DAC) is a hypomethylating drug used in myelodisplastic syndrome, that has been shown to exert immunomodulatory effects. We have evaluated the effects of DAC in two rodent models of GBS, the Experimental Allergic Neuritis (EAN). Both prophylactic and therapeutic treatment with DAC ameliorated the clinical course of EAN, increasing the numbers of thymic regulatory T cells and reducing the production of proinflammmatory cytokines. Our data suggest the possible use of decitabine for the treatment of GBS.

Original languageEnglish
Pages (from-to)41-48
Number of pages8
JournalJournal of Neuroimmunology
Volume321
DOIs
Publication statusPublished - Aug 15 2018

Fingerprint Dive into the research topics of 'Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis'. Together they form a unique fingerprint.

  • Cite this